Andrew Chris, AMFT | |
5300 Adams Ave Pkwy Ste 6, Washington Terrace, UT 84405-6955 | |
(801) 690-6628 | |
Not Available |
Full Name | Andrew Chris |
---|---|
Gender | Male |
Speciality | Marriage & Family Therapist |
Location | 5300 Adams Ave Pkwy Ste 6, Washington Terrace, Utah |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1700301512 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
106H00000X | Marriage & Family Therapist | 10452158-3904 (Utah) | Primary |
Mailing Address | Practice Location Address |
---|---|
Andrew Chris, AMFT 5300 Adams Ave Pkwy Ste 6, Washington Terrace, UT 84405-6955 Ph: () - | Andrew Chris, AMFT 5300 Adams Ave Pkwy Ste 6, Washington Terrace, UT 84405-6955 Ph: (801) 690-6628 |
News Archive
Researchers at the University of North Carolina School of Medicine are conducting studies that utilize blood donations from individuals who have been diagnosed with or potentially exposed to mosquito-borne viruses as part of ongoing dengue and Zika research and vaccine development.
CQ Healthbeat reports the Office of Management and Budget is reviewing several health law implementation rules including this one, which will determine the types of coverage available to consumers. Meanwhile, a study examines how the health law's caps on out-of-pocket costs will affect consumers next year.
Researchers have reported the results of the first randomized clinical trial to test a novel strategy involving waking up and then killing the 'sleeping' HIV that is hiding in the body using an experimental approach known as 'kick and kill'.
Tolera Therapeutics, Inc., was granted orphan drug status by the United States Food and Drug Administration (FDA) for TOL101 (anti-TCR murine monoclonal antibody, type IgM), for treatment of recent onset immune-mediated Type 1 diabetes mellitus (T1DM). Designation is granted for treatment of patients sixteen years of age and younger with immune-mediated T1DM and preserved pancreatic beta-cell function, commonly referred to as juvenile diabetes.
South Korean pharmaceutical company SK Biopharmaceuticals announced that the lead drug, YKP3089, from its drug development program for the treatment of refractory epilepsy, has been awarded funding from the Korea Drug Development Fund to support clinical development for the next three years.
› Verified 6 days ago